Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.

<p><strong>Background:</strong> No specific antiviral drug has been proven effective for treatment of patients with severe coronavirus disease 2019 (COVID-19). Remdesivir (GS-5734), a nucleoside analogue prodrug, has inhibitory effects on pathogenic animal and human corona...

Full description

Bibliographic Details
Main Authors:	Wang, Y, Zhang, D, Du, G, Du, R, Zhao, J, Jin, Y, Fu, S, Gao, L, Cheng, Z, Lu, Q, Hu, Y, Luo, G, Wang, K, Lu, Y, Li, H, Wang, S, Ruan, S, Yang, C, Mei, C, Ding, D, Wu, F, Tang, X, Ye, X, Ye, Y, Liu, B, Yang, J, Yin, W, Wang, A, Fan, G, Zhou, F, Liu, Z, Gu, X, Xu, J, Shang, L, Zhang, Y, Cao, L, Guo, T, Wan, Y, Qin, H, Jiang, Y, Jaki, T, Hayden, FG, Horby, PW, Cao, B, Wang, C
Format:	Journal article
Language:	English
Published:	Elsevier 2020

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.

Similar Items